A Phase 1 interventional study of Camlipixant and Dabigatran etexilate in Cough and Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.
Among the 10 studies testing BLU-5937 in Cough, this one is the 5th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 6th registered.
428 studies on the registry are indexed under Cough; 68 are open to participants now.
Browse Cough studies →1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2023.
This study's enrollment of 45 is below the median of 80 across 320 interventional studies indexed under Cough.
Median enrollment 44 across the 10 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Bellus Health Inc. - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.
14 studies in Cough by GlaxoSmithKline: 1 open now, 2 under way, 2 of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 14 studies in Cough by GlaxoSmithKline, this one is the 5th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 1, and was the 10th registered.
GlaxoSmithKline’s Cough studies by the year they started, since 2011.
1 of the studies testing BLU-5937 in Cough that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07650084Phase 3GlaxoSmithKlineA 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension | 2027-08-27 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing BLU-5937 in Cough, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 14 in Cough:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating potential drug-drug interactions between gemfibrozil (part 1) or dabigatran etexilate (part 2) and camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.
Drug: Camlipixant · Drug: Gemfibrozil
Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1, followed by repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. There was a washout of at least 4 days between the dose of dabigatran etexilate on Day 1 and the dose of camlipixant on Day 5.
Drug: Camlipixant · Drug: Dabigatran etexilate
Camlipixant will be administered
Dabigatran etexilate will be administered
Gemfibrozil will be administered.
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Maximal Observed Concentration (Cmax) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 2: AUC(0-Infinity) of Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: AUC(0-t) of Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Cmax of Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: AUC(0-Infinity) of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: AUC(0-t) of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Cmax of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Terminal Elimination Rate Constant of Camlipixant (Kel)
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Apparent Clearance (CL/F) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 1: Apparent Volume of Distribution (Vz/F) of Camlipixant
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9
Part 2: Tmax of Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: T1/2 Following Administration Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Kel Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: CL/F Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Vz/F Free Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Tmax of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: T1/2 Following Administration of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Kel of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: CL/F of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 2: Vz/F of Total Dabigatran
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)
An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration
Time frame: Day 1 post-dose until Day 5 pre-dose of gemfibrozil [camlipixant 50mg]; from Day 5 dosing until Day 9 pre-dose of camlipixant [gemfibrozil 600mg]; from camlipixant dosing on Day 9 until end of study [Day 21] [camlipixant 50mg+gemfibrozil 600mg]
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs
An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to: taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.
Time frame: Day1 postdose until Day5 predose of camlipixant [dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran [camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day 22][dabigatran etexilate 150mg+camlipixant 50mg]
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings
A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.
Time frame: Day 5, Day 9 pre-dose and 1 hour post-dose, Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings
A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.
Time frame: Day 5, Day 10 and Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate
Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Day 9 and Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate
Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Day 10 and Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination
Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.
Time frame: Up to Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination
Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.
Time frame: Up to Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.
Time frame: Up to Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.
Time frame: Up to Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.
Time frame: Up to Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.
Time frame: Up to Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.
Time frame: Up to Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.
Time frame: Up to Day 13
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.
Time frame: Up to Day 12
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.
Time frame: Up to Day 13
| Milestone | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|---|
| Started | 25 | 0 |
| Safety population | 16 | 0 |
| Completed | 15 | 0 |
| Not completed | 10 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Enrolled but did not receive study treatment | 9 | 0 |
| Milestone | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|---|
| Started | 0 | 20 |
| Safety population | 0 | 16 |
| Completed | 0 | 14 |
| Not completed | 0 | 6 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Enrolled but did not receive study treatment | 0 | 4 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 4886.66 ± 28.69 |
| Day 9 | 10642.07 ± 24.17 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 4846.83 ± 28.84 |
| Day 9 | 10541.57 ± 24.44 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Nanograms per milliliter | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 1078 ± 25.02 |
| Day 9 | 1303 ± 25.65 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 943.49 ± 52.12 |
| Day 10 | 1055.20 ± 43.81 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 920.18 ± 53.11 |
| Day 10 | 1031.89 ± 45.03 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 110 ± 53.53 |
| Day 10 | 125 ± 47.75 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 1165.82 ± 52.34 |
| Day 10 | 1339.35 ± 41.21 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 1139.80 ± 53.51 |
| Day 10 | 1316.80 ± 41.83 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Nanograms per milliliter | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 135 ± 54.20 |
| Day 10 | 160 ± 42.42 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 0.750 (0.500 to 2.000) |
| Day 9 | 0.750 (0.500 to 2.500) |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 5.56 ± 31.80 |
| Day 9 | 9.56 ± 18.60 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
| Percentage of AUC extrapolation | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 0.58 ± 104.04 |
| Day 9 | 0.59 ± 109.24 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| h^-1 | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 0.1247 ± 31.80 |
| Day 9 | 0.0725 ± 18.60 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Liters per hour | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 10.23 ± 28.69 |
| Day 9 | 4.70 ± 24.17 |
Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.
| Liters | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 1 | 82.06 ± 22.57 |
| Day 9 | 64.80 ± 23.69 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 2.000 (1.500 to 3.500) |
| Day 10 | 2.000 (1.500 to 3.000) |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 10.49 ± 18.23 |
| Day 10 | 9.18 ± 9.16 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
| Percentage of AUC extrapolation | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 2.22 ± 49.87 |
| Day 10 | 1.95 ± 52.63 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| h^-1 | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 0.0660 ± 18.23 |
| Day 10 | 0.0755 ± 9.16 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Liters per hour | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 158.98 ± 52.12 |
| Day 10 | 142.15 ± 43.81 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Liters | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 2407.03 ± 54.73 |
| Day 10 | 1883.56 ± 43.72 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 2.000 (1.000 to 3.500) |
| Day 10 | 2.000 (1.000 to 3.000) |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 11.04 ± 30.01 |
| Day 10 | 10.21 ± 16.90 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.
| Percentage of AUC extrapolation | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 1.93 ± 59.97 |
| Day 10 | 1.58 ± 37.14 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| h^-1 | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 0.0628 ± 30.01 |
| Day 10 | 0.0679 ± 16.90 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Liters per hour | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 128.66 ± 52.34 |
| Day 10 | 111.99 ± 41.21 |
Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.
| Liters | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 1 | 2048.49 ± 61.16 |
| Day 10 | 1649.21 ± 37.35 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration
| Participants | Part 1: Camlipixant 50 mg | Part 1: Gemfibrozil 600 mg | Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg |
|---|---|---|---|
| TEAEs | 1 | 6 | 5 |
| TESAEs | 0 | 0 | 1 |
| TEAEMIs | 0 | 0 | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to: taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.
| Participants | Part 2: Dabigatran Etexilate 150 mg | Part 2: Camlipixant 50 mg | Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg |
|---|---|---|---|
| TEAEs | 4 | 6 | 0 |
| TESAEs | 0 | 0 | 0 |
| TEAEMIs | 0 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 5 | 0 |
| Day 9, Pre-dose | 0 |
| Day 9,1-Hour Post-dose | 0 |
| Day 12 | 0 |
A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 5 | 0 |
| Day 10 | 0 |
| Day 13 | 0 |
Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Day 9 | 0 |
| Day 12 | 0 |
Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Day 10 | 0 |
| Day 13 | 0 |
Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature | 0 |
Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature | 0 |
Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination | 1 |
Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination | 0 |
Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters | 0 |
Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters | 0 |
Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters | 3 |
Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters | 1 |
Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters | 0 |
Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters | 0 |
Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.
| Participants | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg |
|---|---|
| Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis | 0 |
Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.
| Participants | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg |
|---|---|
| Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis | 0 |
Collected over Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Camlipixant 50 mg | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Part 1: Gemfibrozil 600 mg | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg | 0/16 (0%) | 1/16 (6.3%) | 5/16 (31.3%) |
| Part 2: Dabigatran Etexilate 150 mg | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Part 2: Camlipixant 50 mg | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Event | Part 1: Camlipixant 50 mg | Part 1: Gemfibrozil 600 mg | Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg | Part 2: Camlipixant 50 mg | Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg |
|---|---|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/16 | 0/16 | 1/16 | 0/16 | 0/15 | 0/14 |
| Event | Part 1: Camlipixant 50 mg | Part 1: Gemfibrozil 600 mg | Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg | Part 2: Camlipixant 50 mg | Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg |
|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 2/15 | 0/14 |
| HeadacheNervous system disorders | 0/16 | 0/16 | 1/16 | 1/16 | 1/15 | 0/14 |
| ConstipationGastrointestinal disorders | 1/16 | 1/16 | 0/16 | 1/16 | 1/15 | 0/14 |
| Faeces softGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| Alanine aminotransferase increasedInvestigations | 0/16 | 1/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 1/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| Gamma-glutamyltransferase increasedInvestigations | 0/16 | 0/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| Dry eyeEye disorders | 0/16 | 0/16 | 0/16 | 0/16 | 1/15 | 0/14 |
| Procedural dizzinessInjury, poisoning and procedural complications | 0/16 | 0/16 | 0/16 | 0/16 | 1/15 | 0/14 |
Baseline characteristics are reported for the Safety Population which consisted of all participants who received at least one dose of any study drug.
| Age, Customized(Participants) | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg | Total |
|---|---|---|---|
| 23 to 54 years | 16 | 16 | 32 |
| Sex: Female, Male(Participants) | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg | Total |
|---|---|---|---|
| Female | 7 | 7 | 14 |
| Male | 9 | 9 | 18 |
| Race/Ethnicity, Customized(Participants) | Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg | Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg | Total |
|---|---|---|---|
| All Other Races | 2 | 2 | 4 |
| White | 14 | 14 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2023 to primary completion in Oct 2023, 2 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion.
Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BLU-5937
Bellus Health Inc. - a GSK company →